Part 4/8:
The White House has clarified that pharmaceuticals from countries with existing trade agreements with the U.S. will be exempt from current tariffs. This move aims to alleviate concerns for companies sourcing from nations like Canada and those within the European Union, which currently accounts for approximately 60% of the $214 billion worth of pharmaceutical imports into the U.S. in 2024.